资本老手拆分轩竹生物闯关IPO “投喂”整合造出高估值

览富财经
24 Dec 2024

《投资者网》蔡俊近期,四环医药(00460.HK,下称“公司”)在忙着拆分上市。四环医药发布公告称,建议分拆轩竹生物赴港上市。2022年、2023年和今年上半年,轩竹生物净亏损分别为5.12亿元、3.01亿元、1.11亿元。此前,轩竹生物计划上市科创板,但随后终止。实际上,该企业自2018年后才由公司独立运营,并通过收购、整合、引进权益等操作提升整体估值。但折戟科创板打乱其资本计划,公司回购轩竹...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10